All In Biotech

Drug Trial Radar · NCT05348200

Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Apr 22, 2022

Primary completion

Apr 20, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
Citius Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Therapeutics, Inc.
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized Phase 2 double blind study which aims to determine the safety and efficacy of CITI-002 cream in adult patients with Goligher's grade II or III hemorrhoids.

Conditions

  • Hemorrhoids

Interventions

  • Monad 1Drug

    Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.

  • Monad 2Drug

    Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.

  • Monad 3Drug

    Single therapy cream containing Halobetasol Propionate (high strength).

  • Combination - CITI-002 (low dose)Drug

    Combination cream containing Lidocaine and HBP (low)

  • Combination - CITI-002 (high dose)Drug

    Combination cream containing Lidocaine and HBP (high)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemorrhoid symptomsTime frame: Day 8

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Site #01

    Huntsville, Alabama

  • Site #07

    Tucson, Arizona

  • Site #06

    Chula Vista, California

  • Site #09

    Pomona, California

  • Site #16

    San Diego, California

  • Site #03

    San Diego, California

  • Site #05

    West Palm Beach, Florida

  • Site #10

    Covington, Louisiana

  • Site #12

    Prairieville, Louisiana

  • Site #02

    Wyoming, Michigan

  • Site #14

    Gulfport, Mississippi

  • Site #08

    Omaha, Nebraska

  • Site #11

    Mentor, Ohio

  • Site #13

    Tulsa, Oklahoma

  • Site #04

    Harrisburg, Pennsylvania

  • Site #15

    McKinney, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.